ORIGINAL RESEARCH article

Front. Immunol.

Sec. Cancer Immunity and Immunotherapy

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1590368

This article is part of the Research TopicCommunity Series in Post-Translational Modifications of Proteins in Cancer Immunity and Immunotherapy, Volume IVView all articles

HMGA2 interacts with KAT6A to regulate MMPs chromatin architecture and promote triple-negative breast cancer metastasis

Provisionally accepted
Lu  QiaoLu Qiao1,2,3Zenghua  LiangZenghua Liang1,2,3Pengyi  MaPengyi Ma1,2,3Shanshan  ZhangShanshan Zhang4Cuiyun  SunCuiyun Sun5,6,7Wenjun  LuoWenjun Luo5,6,7Lin  YuLin Yu1,2,3*
  • 1Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China
  • 2Laboratory of Molecular Immunology, Research Center of Basic Medical Science, Tianjin Medical University, Tianjin, China
  • 3Tianjin Key Laboratory of Cellular and Molecular Immunology and Key Laboratory of the Educational Ministry of China, Tianjin Medical University, Tianjin, China
  • 4Department of Radiology, Tianjin Medical University General Hospital, Tianjin, Tianjin, China
  • 5Department of Neuropathology, Tianjin Key Laboratory of Injuries, Variations and Regeneration of the Nervous System, Tianjin, China
  • 6Key Laboratory of Post-trauma Neuro-repair and Regeneration in Central Nervous System of Education Ministry, Tianjin, China
  • 7Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin, China

The final, formatted version of the article will be published soon.

Background: Triple-negative breast cancer (TNBC), the most lethal breast cancer subtype, demonstrates poor prognosis due to its high rates of metastasis, recurrence, and mortality. The metastatic potential in TNBC patients serves as a critical determinant of clinical outcomes. The high mobility group AT-hook 2 (HMGA2) has emerged as a novel chromatin architectural regulator, its specific role in TNBC metastasis requires further investigation.Methods: We analyzed the expression of HMGA2 in TNBC and non-TNBC patients using Genomic Data Commons (GDC) The Cancer Genome Atlas (TCGA) and immunohistochemistry. The correlation between HMGA2 expression and patient prognosis was assessed using the Kaplan-Meier estimator. The roles of HMGA2 in TNBC metastasis were validated through cell wound healing assay, transwell assay and lung metastatic model. RNA sequencing, chromatin immunoprecipitation, DNA electrophoretic mobility shift, co-immunoprecipitation and chromosome conformation capture assays were applied to identify the mechanisms by how HMGA2 functions as a novel chromatin architectural regulator.Results: Our study revealed significantly upregulated HMGA2 expression in TNBC patients compared to non-TNBC patients. Kaplan-Meier survival analysis demonstrated a strong association between elevated HMGA2 expression and poor prognosis in TNBC cases. Functional studies showed that HMGA2 downregulation markedly inhibited TNBC metastatic progression. Mechanistic investigations revealed that HMGA2 facilitates TNBC metastasis through transcriptional activation of matrix metalloproteinases (MMPs). Specifically, HMGA2 interacted with lysine acetyltransferase 6A (KAT6A) to mediate histone acetylation at MMPs promoter regions. Concurrently, HMGA2 induced chromatin conformation changes to enhance MMPs transcriptional activity.Conclusion: These findings establish that the HMGA2/KAT6A complex promote MMPs expression to drive TNBC metastasis, identifying novel therapeutic targets for this aggressive malignancy.

Keywords: Triple-negative breast cancer, High mobility group AT-hook 2, Matrix Metalloproteinases, lysine acetyltransferase 6A, metastasis

Received: 09 Mar 2025; Accepted: 28 Apr 2025.

Copyright: © 2025 Qiao, Liang, Ma, Zhang, Sun, Luo and Yu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Lin Yu, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, 300060, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.